A 46-year-old cisgender man is seen in a clinic with fatigue and weight loss and is newly diagnosed with HIV. He is seen 2 days later, and review of initial laboratory studies shows an HIV RNA of 74,822 copies/mL and a CD4 count of 35 cells/mm3. A baseline genotypic drug resistance test is pending. He is immediately started on an antiretroviral regimen of dolutegravir and tenofovir alafenamide-emtricitabine.
Based on the Adult and Adolescent OI Guidelines, which one of the following is recommended regarding initiating prophylaxis to prevent disseminated MAC disease in adults with HIV?
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 28th, 2023
September 28th, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5